Tong Fangjia, Geng Jingshu, Yan Bingqing, Lou Huihuang, Chen Xiaohang, Duan Chenwei, He Jing, Zhang Siwei, Xie Huanhuan, Li Huining, Yuan Dawei, Zhang Fengmin, Meng Hongxue, Wei Lanlan
Department of Microbiology, Harbin Medical University, Harbin, China.
Wu Lien-Teh Institute, Harbin Medical University, Harbin, China.
Cell Physiol Biochem. 2018;49(1):206-216. doi: 10.1159/000492858. Epub 2018 Aug 22.
BACKGROUND/AIMS: Human papillomavirus (HPV) is an etiological risk factor for a subset of head and neck squamous cell carcinomas. HPV has been proven to be a powerful prognostic biomarker for oropharyngeal cancer, but its role in the larynx has not been explored in depth. Here, we sought to evaluate the prevalence and genotype distribution of HPV in patients with laryngeal squamous cell carcinoma (LSCC) in northeast China.
HPV DNA in specimens from 211 patients diagnosed with LSCC was analyzed by the polymerase chain reaction and in situ hybridization, and p16 overexpression was evaluated by immunohistochemistry. p16 expression was scored positive if strong and diffuse nuclear and cytoplasmic staining was present in > 75% of tumor cells.
In this study, infection with HPV and p16 expression were not absolutely consistent. Among all patients, 132 (62.6%) were positive for HPV DNA (HPV+), while 23 (10.9%) were inconsistent for HPV and p16. Multivariate analysis indicated that HPV, but not p16, is an independent prognostic factor for overall survival in LSCC. Overall survival was significantly improved in HPV+ LSCC patients compared with the HPV-negative group (hazard ratio, 0.395; 95% confidence interval, 0.185-0.843; p = 0.016). Among the 132 HPV+ patients, 28 (21.2%) were HPV-16 single infection.
This study indicates that HPV DNA is a more reliable surrogate marker than p16 for the prediction of survival in patients with LSCC.
背景/目的：人乳头瘤病毒（HPV）是一部分头颈鳞状细胞癌的病因风险因素。HPV已被证明是口咽癌的一个强大的预后生物标志物，但其在喉癌中的作用尚未得到深入研究。在此，我们旨在评估中国东北地区喉鳞状细胞癌（LSCC）患者中HPV的患病率和基因型分布。
采用聚合酶链反应和原位杂交技术分析211例诊断为LSCC患者标本中的HPV DNA，并通过免疫组织化学评估p16过表达情况。如果>75%的肿瘤细胞中存在强而弥漫的核及细胞质染色，则p16表达评分为阳性。
在本研究中，HPV感染与p16表达并非完全一致。在所有患者中，132例（62.6%）HPV DNA呈阳性（HPV+），而23例（10.9%）HPV与p16结果不一致。多变量分析表明，HPV而非p16是LSCC患者总生存的独立预后因素。与HPV阴性组相比，HPV+ LSCC患者的总生存显著改善（风险比，0.395；95%置信区间，0.185 - 0.843；p = 0.016）。在132例HPV+患者中，28例（21.2%）为HPV-16单一感染。
本研究表明，对于预测LSCC患者的生存，HPV DNA比p16是更可靠的替代标志物。
